PCSK9 inhibitors × lipids

TrialJournal of the American Heart Association2024

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.

Xiaozeng Wang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 806 people · 2024

Not counted

Probably lowered lipids

−67.7percentage points−72.5 to −63.0

As reported

difference −67.7 %, 95% CI −72.5 to −63.0

One number in the abstract

the abstract, start to end

in LDL-C from baseline to week 24 was -67.7% (95% CI, -72.5% to -63.0%;

← favours treatmentfavours comparator →
could be chance
Lipids
−67.7−72.5 to −63.0
PCSK9 inhibitorsLipids
1 / 3

6 papers cite it

2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 38818934